Moxifloxacin: Update and perspectives after 8 years of usage

Expert Review of Respiratory Medicine

Volumn 2, Issue 4, 2008, Pages 443-453

  Lode, Hartmut M ^a   Schmidt Ioanas, Malina ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

Acute bacterial sinusitis; Acute exacerbation of chronic bronchitis; Complicated skin infection; Microbiology; Moxifloxacin; Pharmacology; Pneumonia; Safety; Tuberculosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; ETHAMBUTOL; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; ISONIAZID; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PAZUFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; UNINDEXED DRUG;

ABDOMINAL INFECTION; ACUTE SINUSITIS; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER FAILURE; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; SKIN INFECTION; SKIN TOXICITY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT;

EID: 55149120088     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.4.443     Document Type: Article

References (67)

1. Lesher GY, Froelich EJ, Gruett MD et al. 1,8-naphthyridine derivates: a new class of chemotherapeutic agents. J. Med. Pharm. Chem. 5, 1063-1068 (1962).
2. Andriole VT. The quinolones: past, present and future. Clin. Infect. Dis. 41, S113-S119 (2005).
3. Gellert M, Mizuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl Acad. Sci. USA 73, 3872-3876 (1976).
4. Sugino A, Peebles CL, Krenzrer KN, Cozarrelli NR. Mechanism of action of nalidixic acid: purification of Echerichia coli nalA gene production and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl Acad. Sci. USA 74, 4767-4771 (1977).
5. Brighty KE, Gootz TD. Chemistry and mechanism of action of the quinolone antibacterials. In: The Quinolones (3rd Edition). Andriole VT (Ed.). Academic Press, CA, USA 33-97 (2003).
6. Ho PL, Yung RW, Tsang DN et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48, 659-665 (2001).
7. Johnson AP, Sheppard CL, Harnett SJ et al. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J. Antimicrob. Chemother. 52, 953-960 (2003).
8. Hooper DC. Mechanisms of quinolone resistance. In: Quinolone Antimicrobial Agents (3rd Edition). Hooper DC, Rubinstein E (Eds). American Society of Microbiology Press, Washington DC, USA 41-67 (2003).
9. Jacoby GA. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41, S120-S126 (2005).
10. Zhanel GG, Walkty A, Nichol K, Smith H, Noreddin A, Hoban DJ. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn. Microbiol. Infect Dis. 45(1), 63-67 (2003).
11. Muñoz-Bellido JL, Alonzo Manzanares M, Martínez Andrés JA et al. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob. Agents Chemother. 43(2), 354-356 (1999).
12. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pintA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43(1), 187-189 (1999).
13. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43(2), 415-417 (1999).
14. Robicsek A, Sahm DF, Strahilevitz J, Jacoby GA, Hooper DC. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob. Agents Chemother. 49(7), 3001-3003 (2005).
15. Jones M, Draghi D, Thornsberry C, Sahm D. A current perspective on Streptococcus pneumoniae and Haemophilus influenzae resistance trends in Europe: GLOBAL Surveillance Study, 2005. Clin. Microbiol. Infect. 12(Suppl. 4), 1629 (2006).
16. Johnson AT, Lamagni TL, Wale M et al. Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobia Resistance Surveillance System (EARSS) in 2003. Int. J. Antimicrob. Agents 25, 539-541 (2005).
17. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA; Paul-Ehrlich-Society for Chemotherapy. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int. J. Antimicrab. Agents 23(6), 577-581 (2004).
18. Neuhauser MM, Weinstein TA, Rydman R et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA 289, 885-888 (2003).
19. Mueller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrobial Agents Chemother. 48, 369-377 (2004).
20. Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 41, S127-S135 (2005).
21. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 45, 433-438 (2001).
22. Breilh D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J. Chemother. 15(6), 558-562 (2003).
23. Müller M, Stass H, Brunner M, Möller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob. Agents Chemother. 43(10), 2345-2349 (1999).
24. Schubert S, Dalhoff A, Stass H, Ullmann U. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations. Infection 33(Suppl. 2), 15-21 (2005).
25. Muijsers RB, Jarvis B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 62(6), 967-973 (2002).
26. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int. J. Antimicrob. Agents. 26(5), 357-365 (2005).
27. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann. Surg. 244(2), 204-211 (2006).
28. Finch R, Schurmann D, Collins O et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 46(6), 1746-1754 (2002).
29. Drummond MF, Becker DL, Hux M et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 124(2), 526-535 (2003).
30. Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin. Infect. Dis. 41(12), 1697-1705 (2005).
31. Lode H, Grossman C, Choudhri S et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir. Med. 97(10), 1134-1142 (2003).
32. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH; Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis. 42(1), 73-81 (2006).
33. Torres A, Read R, Lode H et al. Once daily sequential iv/po moxifloxacin is equivalent to iv ceftriaxone plus twice daily iv/po levofloxacin in the treatment of severe community-acquired pneumonia requiring hospitalisation: the MOTIV Study. Presented at: 16th European Congress of Microbiology and Infectious Diseases, Nice, France, 1-4 April, 2006.
34. Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin. Infect. Dis. 41(Suppl. 2), S177-S185 (2005).
35. Wilson R, Allegra L, Huchon G et al; MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125(3), 953-964 (2004).
36. Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP; MOSAIC Study Group. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 61 (4), 337-342 (2006).
37. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treatway G. Efficay and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbation of chronic bronchitis. Int. J. Antimicrobial Agents 29(1), 56-61 (2007).
38. Niederman MS, Anzueto A, Sethi S et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin Phase III trials compared with macrolide agents. Respir. Med. 100(10), 1781-1790 (2006).
39. Miravitlles M, Molina J, Brosa M. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. Arch. Bronchopneumol. 43(1), 22-28 (2007).
40. Ariza H, Rojas R, Johnson P et al. Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis. BMC Ear Nose Throat Disord. 6, 8 (2006).
41. Siegert R, Gehanno P, Nikolaidis P et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir. Med. 94(4), 337-344 (2000).
42. Arrieta JR, Galgano AS, Sakano E et al.; Moxifloxacin in Acute Sinusitis Study (MASS) Latin American Study Group. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Am. J. Otolaryngol. 28(2), 78-82 (2007).
43. Gehanno P, Berche P, Perrin A. Moxifloxacin in the treatment of acute maxillary sinusitis after first-line treatment failure and acute sinusitis with high risk of complications. J. Int. Med. Res. 31(5), 434-447 (2003).
44. Rodríguez JC, Ruiz M, López M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20(6), 464-467 (2002).
45. Peloquin CA, Hadad DJ, Molino LP et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(3), 852-857 (2007).
46. Codecasa LR, Ferrara G, Ferrarese M et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir. Med. 100(9), 1566-1572 (2006).
47. Blumberg HM, Burman WJ, Chaisson RE et al.; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America; treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167(4), 603-662 (2003).
48. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother. 48(3), 780-782 (2004).
49. Nuermberger EL, Yoshimatsu T, Tygi S et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170, 1131-1134 (2004).
50. Burman WJ, Goldberg S, Johnson JL et al.; Tuberculosis Trials Consortium. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174, 331-338 (2006).
51. Koch H, Landen H, Stanch K. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice. Clin. Drug Invest. 24(8), 441-448 (2004).
52. Barth J, Stauch K, Landen H. Sequential intravenous/oral moxifloxacin therapy in pneumonia - results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice. Clin. Drug Invest. 25(11), 691-700 (2005).
53. Koch H, Landen H, Stauch K. Daily-practice treatment of acute exacerbation of chronic bronchitis with moxifloxacin in a large cohort in Germany. Clin. Drug Invest. 24(8), 449-455 (2004).
54. Elies E, Landen H, Stauch K. Moxifloxacin in patients with sinusitis treated in general practice: results of a post-marketing surveillance study. Clin. Drug Invest. 24(8), 431-439 (2004).
55. Faich G, Landen H, Stauch K. Clinical experience with moxifloxacin in patients with respiratory tract infection. Ann. Pharmacother. 38, 749-754 (2004).
56. Schaberg T, Möller M, File T, Stauch K, Landen H. Real-life treatment of acute exacerbation of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice. Clin. Drug Invest. 26(12), 733-744 (2006).
57. Stahlmann R, Lode H. Safety overview: toxicity, adverse events and drug interaction. In: The Quinolones (3rd Edition). Andriole VT (Ed.). Academic Press, CA USA 397-453 (2000).
58. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin. Ther. 26(7), 940-950 (2004).
59. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf. 28(5), 443-452 (2005).
60. Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 128(5), 3398-3406 (2005).
61. Gavin JR 3rd, Kubin R, Choudhri S et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf. 27(9), 671-686 (2004).
62. Woodhead M, Blasi F, Ewig S et al.; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26(6), 1138-1180 (2005).
63. Mandell LA, Wunderink RG, Anzueto A et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
64. Anon JB, Jacobs MR, Poole MD et al.; Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial thinosinusitis. Otolaryngol. Head Neck Surg. 130(1 Suppl.), 1-45 (2004).
65. Kohlhammer Y, Raspe H, Marre R, Suttorp N, Welte T, Schäfer T; CAPNETZ Study Group. Antibiotic treatment of community acquired pneumonia varies widely across Germany. J. Infect. 54(5), 446-453 (2004).
66. Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J. Antimicrob. Chemother. 59(5), 977-989 (2007).
67. Adam HJ, Schurek KN, Nichol KA et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 51(1), 198-207 (2007).